Directorio
We are doing this study to find out if an experimental drug called mosunetuzumab (the study drug) is a safe and effective option for low burden follicular lymphoma. We want to know how well it works in comparison to rituximab, which is the standard drug used to treat people with this diagnosis.
The SYNCHRONICITY study is a test to compare two treatments for people with heart failure and a heart electrical problem called left bundle branch block. People in the study will be randomly chosen to get one of two devices: a new type called LBBAP or a regular type called CRT. First, they will have surgery to put in the device. Then, they will have checkups at 6 months, 12 months, and once a year for up to 5 years. At these visits, doctors will check the device, do heart tests, and ask how the person feels. The study wants to find out which device is safer and works better.
We are doing this study to find out if an experimental drug called STK-012 (the study drug) is a safe and effective treatment for different types of cancer.
We are doing this study to help connect people with type 1 diabetes to research studies they may be eligible to join as participants.
We are doing this study to find out if an experimental drug called mezagitamab (the study drug) is a safe and effective option for people with chronic primary immune thrombocytopenia (ITP). We want to know if adding the study drug to someone's current treatment has any benefit.
We are doing this study to find out if children and young adults with high-grade gliomas who have specific genetic changes (mutations) have better outcomes when they are treated with drugs that "target" those genetic changes. We first need to collect detailed information about the genetic changes within participants' brain tumors. If someone's brain tumor has a targeted genetic change, they may be eligible to participate in a clinical trial with a drug that specifically targets those genetic changes.
We are doing this study to find out if an experimental drug called TL-895 (the study drug) is a safe and effective option for people with indolent systemic mastocytosis.